Do Analysts Agree on Gilead Sciences, Inc. (GILD) Stock's Target Price?

Wednesday, March 25, 2020 3:34 PM | InvestorsObserver Analysts

Wall Street is positive on Gilead Sciences, Inc. (GILD). On average, analysts give the stock a Buy rating. The average price target is $78.421, which means analysts expect the stock to increase by 11.31% over the next twelve months.

That average ranking earns the stock an Analyst Rating of 38, which is better than 38% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.9
Wall Street analysts are rating GILD a Buy today. Find out what this means to you and get the rest of the rankings on GILD!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.

InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Gilead Sciences, Inc. Stock Today?

Gilead Sciences, Inc. (GILD) stock is lower by -4.75% while the S&P 500 has risen 4.26% as of 3:33 PM on Wednesday, Mar 25. GILD is down -$3.51 from the previous closing price of $73.96 on volume of 17,705,569 shares. Over the past year the S&P 500 is lower by -9.46% while GILD has risen 9.67%. GILD earned $4.22 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 16.72.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 73% with an annual plan

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

Related Articles

Asian ADRs Move Lower in Wednesday Trading

European ADRs Edge Higher in Wednesday Trading

Industry Analysis: Should You Buy Anthem Inc (ANTM) in Health Care Plans?

How Does Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rank Against the Competition?

How Does ACADIA Pharmaceuticals Inc. (ACAD) Stock Rank Against the Competition?

Related Companies